Omeros Corporation's third quarter 2026 results mark an important checkpoint for a biotechnology firm that has moved from pre-revenue development into commercial operations. With YARTEMLEA now serving as the main revenue source following its FDA approval for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), each report tests how well the product is executing commercially and gaining reimbursement traction. I am watching closely to see whether the drug can keep delivering sequential growth, broaden outpatient use, and help steer the company toward steadier profitability. Balance sheet items linked to the 2029 convertible notes also add layers of non-cash volatility that can obscure the underlying operational picture.
For the period ended September 30, 2026, Omeros posted adjusted net income of $4.7 million, or $0.06 per share, which cleared the consensus estimate of $0.01 per share. YARTEMLEA gross revenue reached $41.8 million, reflecting a 29.6% sequential increase from $32.2 million and surpassing the approximate $37.3 million analyst target. Net revenue advanced 26% to $35.9 million from $28.5 million in the previous quarter. I also checked this using Tickeron’s AI Screener to compare the stock with peers in the biotech space.
On a GAAP basis, the company recorded a net loss of $57.4 million, or $0.79 per share, largely due to a $62.0 million non-cash mark-to-market loss on a derivative tied to the 2029 convertible notes. Setting those items aside, performance improved year-over-year. Operating income climbed to $4.5 million from $0.1 million, and operating cash flow stayed positive at $13.3 million. The gross-to-net adjustment widened to 14.0% from 11.5%, reflecting higher 340B program purchases that management views as a sign of expanding customer reach.
Even with the beats on adjusted earnings and revenue, shares of OMER declined roughly 10% in after-hours trading. The move appears driven by several factors. The larger GAAP loss, stemming from the non-cash derivative adjustment, drew attention from some investors. In addition, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion in October 2026 on the marketing authorization application for narsoplimab in TA-TMA after re-examination. While the U.S. launch continues as planned, the European development tempers expectations for broader international revenue potential.
The key question ahead centers on whether YARTEMLEA can sustain its growth trajectory in the United States. Management has highlighted expanding adoption at transplant centers, broader formulary inclusion, and greater outpatient utilization as important drivers. Keeping an eye on the gross-to-net adjustment will be useful, as increased 340B participation can weigh on net revenue while pointing to a larger customer base.
Regulatory news will also stay in focus. The negative CHMP opinion on narsoplimab narrows near-term options outside the U.S., so any updates on appeals or next steps merit attention. On the financial side, maintaining positive operating cash flow and handling obligations related to the 2029 notes will influence how the market assesses balance-sheet considerations.
Pipeline updates provide additional context over time. Omeros is advancing next-generation MASP-2 programs, the OMS527 candidate for cocaine use disorder, and its oncology efforts. While these represent longer-term opportunities, meaningful data or milestones could shift attention toward the company’s wider therapeutic reach beyond YARTEMLEA. Investors should balance commercial progress, regulatory outcomes, and pipeline developments rather than viewing any single quarter in isolation.
When evaluating names like OMER alongside other biotechs, I find Tickeron’s AI Screener helpful for quickly filtering technical patterns, fundamentals, and performance metrics. It lets me scan for comparable opportunities without spending hours on manual review, which keeps my process more efficient as market conditions evolve.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Oscillator for OMER moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 28 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Following a +8.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMER advanced for three days, in 217 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
OMER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 58 cases where OMER's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OMER as a result. In 69 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for OMER turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
OMER moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OMER crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for OMER entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-23.853) is normal, around the industry mean (3.586). P/E Ratio (8.812) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (35.714) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. OMER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of pharmaceutical products
Industry Biotechnology